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HistoricalBackground.TheISGcriteriaforBehcet’s,createdin1990,haveexcellentspeciﬁcity,butlacksensitivity.TheInternational
Criteria for Behcet’s Disease (ICBD) was created in 2006, as replacement to ISG. The aim of this study was to compare their
performance. ISG and ICBD Criteria. For ISG oral aphthosis is mandatory. The presence of any two of the following (genital
aphthosis, skin lesions, eye lesions, and positive pathergy test) will diagnose/classify the patient as BD. For ICBD, vascular lesions
were added, while oral aphthosis is no more mandatory. Getting 3 or more points diagnose/classify the patient as BD (genital
aphthosis 2 points, eye lesions 2 points, and the remaining each one point). Performance and Comparison of ISG and ICBD.
Their sensitivity, speciﬁcity, and accuracy (percent agreement), were tested in three independent cohort of patients from Far-
East (China), Middle-East (Iran), and Europe (Germany). The sensitivity for ISG was respectively 65.4%, 78.1%, 83.7% and for
ICBD 87%, 98.2%, and 96.5%. The speciﬁcity for ISG was 99.2%, 98.8%, 89.5% and for ICBD 94.1%, 95.6%, and 73.7%. The
accuracy for ISG was 74.2%, 85.5%, 85.5% and for ICBD 88.9%, 97.3%, and 89.5%. Conclusion. ICBD has better sensitivity, and
accuracy than ISG.
1. HistoricalBackground
Although Behcet’s Disease (BD) is relatively a young disease
(described in 1937), it has already 16 sets of diagno-
sis/classiﬁcation criteria. The ﬁrst of them was proposed by
Curth in 1946, less than 10 years after the description of
the disease [1]. It was followed by Hewitt et al. in 1969 [2],
Mason and Barnes in 1969 [3], Hewitt et al. revised in 1971
[4], Japan in 1972 [5], Hubault and Hamza in 1974 [6],
O’Duﬀy in 1974 [7], Chen in 1980 [8], Dilsen et al. in 1986
[9], Japan revised in 1988 [10], International Study Group
(ISG) in 1990 [11], Iran in 1993 [12], Classiﬁcation Tree in
1993[13],Dilsenrevisedin2000[14],Koreain2003[15,16],
and the International Criteria for Behcet’s Disease (ICBD) in
2006 [17–19].
The ISG criteria were created in 1990 to bring a
consensus on one set of criteria by the collaboration of
France, Iran, Japan, Tunisia, Turkey, UK, and USA. With the
sensitivity of ISG criteria being low [12, 20–25], during the
ﬁrst International Workshop of Behcet’s Disease in Kuhtai
(Austria), it was decided to create an international team to
evaluate the performance of ISG criteria and to compare it
with the existing BD criteria and revise it if necessary.
The ITR-ICBD team was founded in 2004 with the
participation of 27 countries (Austria, Azerbaijan, China,
Egypt, France, Germany, Greece, India, Iran, Iraq, Israel,
Italy, Japan, Jordan, Libya, Morocco, Pakistan, Portugal,
Russia, Saudi Arabia, Singapore, Spain, Taiwan, Thailand,
Tunisia, Turkey, and USA). The International Criteria for
Behcet’s Disease (ICBD) were presented to the International
Conference of Behcet’s Disease in Lisbon (Portugal) in 2006.
Originally it had two formats, like the Iranian criteria. Later,
it was decided to keep only the traditional format [17–19].
The ICBD were presented to the 2007 World Congress of
Dermatology in Argentina and to 2009 ACR congress of
Rheumatology in the USA [19].
2.ISGandICBD Criteria
The ISG criteria [11]u s e5i t e m s .T w oi t e m sa r em u c o u s
membrane manifestations. They are oral aphthosis (OA) and
genitalaphthosis(GA).Thethirditemisskinmanifestations,
comprising pseudofolliculitis (PF) and erythema nodosum
(EN). The forth item is ocular manifestations. They are
anterior uveitis (AU), posterior uveitis (PU), and retinal2 Pathology Research International
vasculitis (RV). The ﬁfth item is the presence of pathergy
phenomenon (PP). It is detected by the pathergy test [26–
30]. In ISG criteria, the presence of OA is mandatory. Two
other items from the 4 remaining (GA, skin, eye, PP) are
necessary to classify a patient as having BD.
For the international criteria, the ICBD [17–19], vascular
manifestations (VMs) have been added to the 5 items of ISG
criteria, because they are one of the characteristics of BD,
and were used in many criteria before the advent of ISG
(Mason and Barnes, Hewitt, Hubault and Hamza, Dilsen,
Japan revised, and Dilsen revised criteria). VM is deﬁned
as superﬁcial phlebitis, deep vein thrombosis, large vein
thrombosis, arterial thrombosis, and aneurysm. Therefore,
ICBD use six items: OA, GA, skin (PF, EN), eye lesions (AU,
PU, RV), VM, and PP. In the ICBD, genital aphthous lesions
and eye lesions have more diagnostic value than the others.
Theygeteach2points.Theother4items(OA,skin,VM,PP)
get one point each. A patient has to get 3 or more points to
be diagnosed/classiﬁed as having BD.
3. Performance and Comparison of
ISGandICBD
Many ways and methods can be used to evaluate the
performance of a criteria set. The most common used are
sensitivity, speciﬁcity, and accuracy. Other methods are the
positive predictive value, the negative predictive value, the
positive likelihood ratio, the negative likelihood ratio, the
diagnostic odds ratio, and Youden’s index [35–39].
Sensitivity is the number of BD patients correctly classi-
ﬁed (diagnosed) by the criteria. It is expressed as percentage
(number of diagnosed BD patients, divided by the total
number of BD patients, and then multiplied by 100) [35].
The sensitivity of ISG in their cohort of 886 patients was
92% [11]. The 95% conﬁdence interval (95% CI) was 90%
to 93.6%. The sensitivity of ICBD in their cohort of 2556BD
patients was 96.1% (95% CI 95.3–96.8). By chi-square test
the diﬀerence between the two sets of criteria is statistically
signiﬁcant (χ2= 23.439, P<0.001). The sensitivity of ISG in
the ICBD cohort of patients was 82.4% (95% CI80.9–83.9).
Itis important tolook atthesensitivity of thetwocriteria
in independent cohort of patients. Three studies validated
the ICBD in their cohort of patients: Germany in 2008 [31],
China in 2008 [32], and Iran in 2010 [33]. The sensitivity
of ISG was, respectively, 83.7% (95% CI 74.3–90.1), 65.4%
(95% CI 60.2–70.5), and 78.1% (95% CI 77–79.1). The
sensitivity of ICBD was, respectively, 96.5% (95% CI 89.7–
99.2), 87% (95% CI 82.8–90.2), and 98.2% (95% CI 97.8–
98.5).
Table 1 shows the sensitivity of ISG in diﬀerent cohort of
patients from diﬀerent parts of world [11, 12, 17–24, 31–33].
Speciﬁcity is the number of non-BD patients, correctly
recognized as not having BD. It is expressed as percentage
(number of non-BD patients correctly recognized as not
having BD, divided by the total number of non-BD patients,
then multiplied by 100) [35]. The speciﬁcity of ISG criteria
in their own cohort of patients was 97% (95% CI 90.8–
99.3). However, the number of control patients was only
Table 1: Sensitivity of diﬀerent classiﬁcation/diagnosis criteria.
Study Reference Number Criteria Sensitivity
% 95% CI
ISG 1990 [11] 886 ISG 92 90.0–93.6
ICBD — —
Iran 1993 [12, 13] 2069 ISG 86.2 84.6–87.6
ICBD — —
China 1996 [20] 79 ISG — —
ICBD — —
APLAR 1998 [21] 216 ISG 72.2 65.9–77.8
ICBD — —
Russia 2000 [22] 105 ISG 79.8 71.2–86.6
ICBD — —
USA 2000 [23] 164 ISG 75.6 68.4–81.6
ICBD — —
India 2004 [24] 50 ISG 72 58.2–82.6
ICBD — —
Singapore 2004 [24] 37 ISG 46 31.1–61.6
ICBD — —
China 2004 [24] 98 ISG 81 71.6–87.3
ICBD — —
Korea 2004 [24] 1454 ISG 58 55.4–60.5
ICBD — —
Iran 2004 [24] 4900 ISG 82 80.9–83.0
ICBD — —
ICBD 2006 [17–19] 2556 ISG 82.4 80.9–83.8
ICBD 96.1 95.3–96.8
Germany 2008 [31] 86 ISG 83.7 74.3–90.1
ICBD 96.5 89.7–99.2
China 2008 [32] 322 ISG 65.4 60.2–70.5
ICBD 87 82.8–90.2
IRAN 2010 [33] 6128 ISG 78.1 77.0–79.1
ICBD 98.2 97.8–98.5
95% CI: 95% conﬁdence interval.
97, and all other control patients having oral aphthosis were
discarded from the original cohort of control patients [34].
The speciﬁcity of ICBD in their cohort of patients was 88.7%
(95% CI 86.8–90.4). The speciﬁcity of ISG and ICBD in
Germany, China, and Iran was, respectively, 89.5%, 99.2%
and 98.8% (ISG), and 73.7%, 94.1%, and 95.6% (ICBD).
Table 2 shows the speciﬁcity of diﬀerent criteria in diﬀerent
studies.
Accuracy orpercentagreementistheabilityofthecriteria
tocorrectlyrecognizeBDpatientsfromthenon-BDpatients.
It is also expressed by percentage (number of diagnosed BD
patients + number of non-BD patients correctly recognized
as not having BD, divided by the total number of BD patients
+ total number of non-BD patients, and then multiplied
by 100) [35]. The accuracy of ISG in their own cohort of
patients was 92% (95% CI 90.1–93.5). The accuracy of ICBD
in their own cohort of patients was 93.8% (95% CI 93–
94.5). The accuracy of ISG and ICBD in Germany, China,
and Iran was, respectively, 85.5%, 7402% and 85.5% (ISG),Pathology Research International 3
Table 2: Speciﬁcity of diﬀerent classiﬁcation/diagnosis criteria.
Study Reference Number Criteria Speciﬁcity
% 95% CI
ISG 1990 [11] 97 ISG 97.0 90.8–99.3
ICBD — —
Iran 1993 [12, 13] 1540 ISG 97.5 96.6–98.2
ICBD — —
China 1996 [20] 35 ISG 79.8 63.7–90.1
ICBD — —
APLAR 1998 [21] 145 ISG 99.3 95.7–100
ICBD — —
Russia 2000 [22] 233 ISG 99.8 98.0–100
ICBD — —
ICBD 2006 [17–19] 1163 ISG 96.0 94.6–96.9
ICBD 88.7 86.8–90.4
Germany 2008 [31] 38 ISG 89.5 75.1–96.3
ICBD 73.7 57.8–85.1
China 2008 [32] 118 ISG 99.2 94.8–100
ICBD 94.1 88.0–97.3
IRAN 2010 [33] 3400 ISG 98.8 98.4–99.1
ICBD 95.6 94.8–96.2
95% CI: 95% conﬁdence interval.
Table 3: Accuracy of diﬀerent classiﬁcation/diagnosis criteria.
Study Reference Number Criteria Accuracy
% 95% CI
ISG 1990 [11] 983 ISG 92 90.1–93.5
ICBD — —
Iran 1993 [12, 13] 3609 ISG 91 90.0–91.9
ICBD — —
China 1996 [20] 114 ISG 79.8 71.4–86.2
ICBD — —
APLAR 1998 [21] 361 ISG 85.8 81.9–89.1
ICBD — —
Russia 2000 [22] 338 ISG 89.8 86.2–92.7
ICBD — —
ICBD 2006 [17–19] 3719 ISG 86.7 85.6–87.7
ICBD 93.8 93.0–94.5
Germany 2008 [31] 124 ISG 85.5 78.1–90.7
ICBD 89.5 82.7–93.8
China 2008 [32] 450 ISG 74.2 70.0–78.0
ICBD 88.9 85.6–91.5
IRAN 2010 [33] 9528 ISG 85.5 84.8–86.2
ICBD 97.3 97.0–97.6
95% CI: 95% conﬁdence interval.
and 89.5%, 88.9%, and 97.3% (ICBD). Table 3 shows the
accuracy of diﬀerent criteria in diﬀerent studies.
Positive predictive value (PPV) demonstrates the prob-
ability that the positive test be true positive. PPV is more
inﬂuenced by speciﬁcity than sensitivity. A criteria set with
90% sensitivity and 90% speciﬁcity will have a PPV of 90.
If sensitivity increases to 95, PPV will improve to 90.5%,
while if speciﬁcity increases to 95%, PPV will improve to
94.8%. PPV is also greatly inﬂuenced by the prevalence of
the disease. Taking the above example, the PPV remains the
same (90) in a dedicated BD clinic, where 50% of patients
have BD and 50% are controls (patients mimicking BD but
arenottrueBD).Inthegeneralpopulation,withaprevalence
of 80 for 100,000 inhabitants, the PPV becomes only 0.72.
Therefore the results calculated in a speciﬁc setting cannot
be used in another setting [33]. The PPV was higher for
ISG than ICBD criteria in the 3 independent set of patients;
however,thediﬀerencewasverysmallintheIranianpatients,
only 2.8% (Table 4).
Negative predictive value (NPV) indicates the probability
of a negative test to be a true negative. The NPV also is
inﬂuenced by the prevalence of the disease. On the contrary
of PPV, the NPV is more inﬂuenced by sensitivity than
speciﬁcity. It is also highly inﬂuenced by the prevalence of
the disease [33].
Positive likelihood ratio (PLR) demonstrates the odds of
having the disease. If PLR is superior to 5, it means that
the test is related to the disease. It is highly inﬂuenced by
speciﬁcity, as is the PPV. It is why the PLR is much higher
for ISG criteria than ICBD (Table 4). Higher PLR for ISG
means that, if ISG is positive, the chance of having BD is very
high, but unfortunately ISG was negative in around 18% of
subjects, in the 3 independent sets (Table 1).
Negative likelihood ratio (NLR) shows the odds of not
havingthedisease.Itishighlyinﬂuencedbythesensitivity,as
for the NPV. It has therefore better values for ICBD than for
ISG criteria (Table 4). The high NLR for ICBD means that, if
ICBD are negative, there are little chances for the patient to
haveBD(only2%errorratefortheIranianpatients:Table 4).
Diagnostic odds ratio ( D O R )i san e ww a yt os h o wh o w
much a test is reliable, like combining the PLR and NLR
results. If DOR is 1, it means the test (criteria) does not
discriminate between the patient and the control. The power
of discrimination increases with higher values of DOR. The
DOR of ISG is 294 and of ICBD is 1185 in the Iranian
patients, demonstrating the high discriminative power of
ICBD over ISG (Table 4).
Youden’s index (YI) is a rather old (1950) and simple cal-
culation, combining the results of sensitivity and speciﬁcity,
to show the performance of the diagnosis criteria. The result
goes from zero to one. The more the result approaches 1,
the higher the performance of the test is. The ideal is one,
meaning a sensitivity and a speciﬁcity of 100%. A sensitivity
and a speciﬁcity of 90% will give a YI of 0.8. The YI of ISG is
inferior to ICBD in China and Iran (Table 4).
4. Conclusion
ICBD are the latest diagnosis/classiﬁcation criteria, created
by the participation of 27 countries from diﬀerent parts of
the world. The large number of Behcet’s disease patients and
control patients, from inside and outside of the Silk Road,
assures the variability needed to create an international cri-
teria that can work in any country with diﬀerent ethnicities.4 Pathology Research International
Table 4: Predictive value, likelihood ratio, diagnostic odds ratio, and Youden’s index.
Study Reference Criteria PPV NPV PLR NLR DOR YI
ISG 1990 [11] ISG 96.8 92.4 30.7 0.08 371.8 0.89
ICBD — — — — — —
Iran 1993 [12, 13] ISG 97.2 87.6 34.5 0.14 243.6 0.84
ICBD — — — — — —
APLAR 1998 [21] ISG 99.0 78.1 103.1 0.28 368.4 0.71
ICBD — — — — — —
Russia 2000 [22] ISG 99.7 83.2 399 0.20 1971 0.80
ICBD — — — — — —
ICBD 2006 [17–19] ISG 95.4 84.5 20.6 0.18 112.4 0.78
ICBD 89.5 95.8 8.5 0.04 193.4 0.85
Germany 2008 [31] ISG 88.8 84.6 7.97 0.18 43.8 0.73
ICBD 78.6 95.5 3.67 0.05 77.3 0.70
China 2008 [32] ISG 98.8 74.1 81.7 0.35 234.4 0.65
ICBD 93.6 87.9 14.7 0.14 106.7 0.81
IRAN 2010 [33] ISG 98.5 81.9 65.1 0.22 294 0.77
ICBD 95.7 98.2 22.3 0.02 1185 0.94
PPV: positive predictive value, NPV: negative predictive value, PLR: positive likelihood ratio, NLR: negative likelihood ratio, DOR: diagnostic odds ratio, and
YI: Youden’s index.
The validation of the criteria in the Far East, Middle-East,
and Europe demonstrates its validity.
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